PreDiabetes Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

PreDiabetes Overview

PreDiabetes is a metabolic disorder that is considered as a precursor for the development of diabetes mellitus. It is characterized by higher than normal blood glucose levels that has not yet reached diabetic levels. The exact cause of prediabetes is unknown, but family history and genetics appear to play an important role.

“PreDiabetes Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PreDiabetes Market.

The PreDiabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the PreDiabetes Pipeline Report:

• Companies across the globe are diligently working toward developing novel PreDiabetes treatment therapies with a considerable amount of success over the years. PreDiabetes Key players such as – NanoPrecision Medical, Caelus Health, Inversago Pharma Inc., Haisco Pharmaceutical Group Co., Ltd., Valbiotis, and others, are developing therapies for the PreDiabetes treatment 
• PreDiabetes Emerging therapies such as – OKV-119, Anaerostipes rhamnosivorans, Intestinimonas, INV-202, HSK7653, Eubacterium Hallii, Totum-63, and others are expected to have a significant impact on the PreDiabetes market in the coming years.   
• Valbiotis initiated a trial titled, “Randomized Placebo-controlled Double-blinded Study of theEffect of TOTUM-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia’

Route of Administration

PreDiabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

PreDiabetes Pipeline Therapeutics Assessment

• PreDiabetes Assessment by Product Type
• PreDiabetes By Stage and Product Type
• PreDiabetes Assessment by Route of Administration
• PreDiabetes By Stage and Route of Administration
• PreDiabetes Assessment by Molecule Type
• PreDiabetes by Stage and Molecule Type

DelveInsight’s PreDiabetes Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the PreDiabetes Therapeutics Market include:

Key companies developing therapies for the PreDiabetes treatment are – Resverlogix Corporation, Boston Therapeutics, vTv Therapeutics, Valbiotis, BioTeSys, SynDevRx, Caelus Health, NanoPrecision Medical, and others

Emerging PreDiabetes Drugs Under Different Phases of Clinical Development Include:

• OKV-119: NanoPrecision Medical
• Anaerostipes rhamnosivorans: Caelus Health
• Intestinimonas: Caelus Health
• INV-202: Inversago Pharma Inc.
• HSK7653: Haisco Pharmaceutical Group Co., Ltd.
• Eubacterium Hallii: Caelus Health
• Totum-63: Valbiotis

Get a Free Sample PDF Report to know more about PreDiabetes Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/prediabetes-pipeline-insight

PreDiabetes Pipeline Analysis:

The PreDiabetes pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of PreDiabetes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PreDiabetes Treatment.
• PreDiabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• PreDiabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PreDiabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further PreDiabetes product details are provided in the report. Download the PreDiabetes pipeline report to learn more about the emerging PreDiabetes therapies

PreDiabetes Pipeline Market Drivers

• Increase in prevalence of prediabetes
• Increase in Diagnosis and Growing investments in research and development

PreDiabetes Pipeline Market Barriers

• Side effects associated with Drugs
• Lack of Awareness among Patients

Scope of PreDiabetes Pipeline Drug Insight    

• Coverage: Global
• Key PreDiabetes Companies: NanoPrecision Medical, Caelus Health, Inversago Pharma Inc., Haisco Pharmaceutical Group Co., Ltd., Valbiotis, and others
• Key PreDiabetes Therapies: OKV-119, Anaerostipes rhamnosivorans, Intestinimonas, INV-202, HSK7653, Eubacterium Hallii, Totum-63, and others
• PreDiabetes Therapeutic Assessment: PreDiabetes current marketed and PreDiabetes emerging therapies
• PreDiabetes Market Dynamics: PreDiabetes market drivers and PreDiabetes market barriers 

Request for Sample PDF Report for PreDiabetes Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about PreDiabetes drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com